26 September 2019 - Deborah Wilkes
Nestlé Health Science has taken a stake in Before Brands, Nature's Sunshine Products is entering the cannabidiol (CBD) market in the US, and Venture Life has released financial results.
Nestlé invests in Before Brands
Nestlé Health Science has taken a stake in Before Brands, the US-based company that specialises in early childhood allergy prevention.
The Swiss business said it had acquired a "significant minority stake" in Before Brands as well as exclusive licensing rights to the company's products outside the US. Nestlé Health Science also has an option to purchase the rest of Before Brands.
Before Brands is the inventor of SpoonfulOne, a line of nutritional products designed to reduce the risk of healthy babies developing a food allergy.
The core technology, which trains a child's immune system through consistent feeding over months to years, is licensed from Stanford University in the US.
Greg Behar, chief executive officer of Nestlé Health Science, said studies had shown that "consistently exposing children at a very early age to a potential food allergen can reduce the development of an allergy to that food by up to 80%".
"It would be very difficult for parents to achieve this kind of consistent immune-system training to 16 different allergens on their own," added Behar.
Before Brands says SpoonfulOne products are made with its Foundational Food Blend and include foods responsible for 90% of food allergies.
The range includes a Mix-In that can be added to food and Puffs that provide a convenient snack.
Financial details of the deal were not disclosed.
Nature's Sunshine expands into CBD
Nature's Sunshine Products is entering the CBD market in the US with a full line of hemp-derived products.
President and chief executive officer Terrence Moorehead said the products were "unique" and took CBD to the "next level by redefining quality and performance". "Nature's Sunshine is uniquely qualified to take the fast-growing CBD industry in the right direction and offer consumers the best, most reliable products on the market," added Moorehead.
The US-based vitamins, minerals and supplements (VMS) company said the CBD products would be released "across multiple distribution channels". "Strong emphasis will be placed on traceability and improved sourcing," stated the company, adding that it would deliver "active compounds that offer better performance, quality and transparency than any other company in the market while improving the overall consumer experience".
Venture Life releases results
Self-care group Venture Life reported sales of GBP9.4 million (USD11.6 million) in the first half of 2019, representing a rise of 14% compared to the same period a year earlier.
The UK-based company said sales by its Brands business had increased by 22% to GBP2.8 million, following the acquisition of the Dentyl mouthwash in August 2018.
Sales of the oral-care products UltraDEX and Dentyl in the UK accounted for GBP2.4 million of this figure, with the rest coming from international sales. UltraDEX generated sales of GBP1.3 million, while Dentyl generated sales of GBP1.1 million.
Sales by the Customer Brands business, which develops and manufactures products on behalf of third parties, were up by 10% to GBP6.6 million.
Adjusted Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) increased by 5.5% to GBP0.7 million.